FullHope
富禾生醫股份有限公司
FullHope is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is EBaT8 (Phase 1/2a trial authorized, EBV-associated nasopharyngeal carcinoma), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| EBaT8 | — | Phase 1/2a trial authorized | EBV-associated nasopharyngeal carcinoma | Taiwan | 2026-04-09 | Company disclosure |
Key events
- Business update (company filing)
Related Drugnews articles
No related articles in this language.